BLLN US Equity☆

FCF runs above owner earnings — under-maintenance or a working-capital release is flattering current cash.

Synthetic rating = ICR-based credit-quality read (Damodaran), not an agency rating. ⚠ coverage rests on a very small interest figure; the letter may overstate quality.

Flows TTM (last 4 quarters); latest annual for: EPS (Diluted), Revenue, EBIT, Net Income, Gross Profit, Interest Expense · EPS TTM $0.14 · revenue TTM $305.1M · FCF TTM $15.7M

• Synthetic-rating coverage uses the latest fiscal year's EBIT over the SAME year's interest expense (no trailing-twelve-month interest could be formed from the quarterly tagging) — a matched-window ratio, never TTM earnings over annual interest.
• Cash-flow figures use the latest fiscal year: this filer tags quarterly cash flows year-to-date only and the missing discrete quarters could not be derived (irregular fiscal quarters or a tagging change), so no four consecutive quarters exist to sum.
• No four consecutive quarters could be summed for EPS (Diluted), Revenue, EBIT, Net Income, Gross Profit, Interest Expense; these figures use the latest fiscal year, not a trailing twelve months.

Output of a disclosed model whose assumptions may be wrong — research information, not investment advice. See the Disclaimer.

No metric cleared the monthly-observation floor for this name — the archive covers 4,673 of the universe's names and reconstructs the per-share tier for US 10-K filers only.

• P/E — P/E history suppressed for this name — pe: per-share basis changed ~0.4x since the reported FY (stock split) — P/E rebased to market cap ÷ net income. The historical pass re-bases per-share facts from the SEC split calendar and has no equivalent guard, so its multiples are on the stale basis; a band over them would be a wrong number.
• ROE — no reconstructed observations for this name and metric.
• ROIC — no reconstructed observations for this name and metric.
• Net Margin — only 5 monthly observations — under the 12-month floor for a series line.
• 12M Momentum — no reconstructed observations for this name and metric.
• EPS Growth 3Y — P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
• Sales Growth 3Y — no reconstructed observations for this name and metric.
• Market Cap — not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.

Loading the monthly cohort placement…

Compared against all 1053 Health Care names we cover — one sector-wide pool, so the median skews toward smaller (often unprofitable) companies. Try the Size band for a cap-matched read.

Held-with peers…

Peers by disclosure language…